secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inari Medical, Inc. (—)
CIK:        0001531048
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268698
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inari Medical to acquire LimFlow for $250M cash, plus up to $165M in milestones
-------------------------------------------------------------------------------

- Upfront purchase price of $250M in cash; contingent payments up to $165M based on commercial and reimbursement milestones.
- LimFlow's TADV system received FDA approval in Sept. 2023; targets no-option CLTI patients facing amputation.
- Transaction expected to close in Q4 2023; financed with cash on hand and borrowings under expanded credit facility.
- Credit facility amended: revolver increased from $40M to $75M; BSBY rate + 1.60%-2.10% margin for new loans.
- Inari sees CLTI as a $1.5B annual U.S. opportunity; conservative estimate of 55,000 treatable patients per year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/d561000d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer